Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18073156 | 0.88 | ALDH1A1 (0.48) | ALDH1A1PTGER4TSHRMPOHPGD | |
| SCHEMBL3592059 | 0.87 | PTGER4 (0.48) | ALDH1A1PTGER4HPGDATMKDM4E | |
| SCHEMBL2556362 | 0.84 | PTGER4 (0.49) | PTGER4 | |
| SCHEMBL18073157 | 0.84 | ALDH1A1 (0.44) | ALDH1A1PTGER4TSHRMPOHPGD | |
| SCHEMBL15880124 | 0.84 | ROCK1 (0.48) | ALDH1A1PTGER4ATMCYP1A2KDM4E | |
| SCHEMBL3606313 | 0.84 | MPO (0.61) | ALDH1A1PTGER4MPOHPGDCYP2C9 | |
| SCHEMBL18073158 | 0.82 | ALDH1A1 (0.43) | ALDH1A1PTGER4TSHRMPOHPGD | |
| SCHEMBL25969261 | 0.81 | PTGER4 (0.46) | PTGER4 | |
| SCHEMBL30615586 | 0.80 | PTGER4 (0.47) | PTGER4MPOATM | |
| SCHEMBL1563562 | 0.78 | KDM5A (0.48) | ALDH1A1PTGER4TSHRHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4633/4885PTGER4 2573/4885TSHR 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.